Author Archives: Patricia Inacio, PhD

Benefits of Orenitram for PAH Patients Detailed in New Data

United Therapeutics’ Orenitram (treprostinil) improves heart function and lowers risk status in people with pulmonary arterial hypertension (PAH) who had begun treatment with another approved therapy, new data from a Phase 3 clinical trial show. Moreover, compared with Actelion’s Uptravi (selexipag), treatment with Orenitram was linked to significantly…

Exosomes from Stem Cells May Slow Vascular Remodeling in PAH

Small vesicles, called exosomes, released by mesenchymal stem cells helped to ease vascular remodeling in a rat model of pulmonary hypertension (PH), a study reports. The study “Mesenchymal stromal cell-derived exosomes improve pulmonary hypertension through inhibition of pulmonary vascular remodeling” was published in the journal …

PH-HFpEF Patients Show Initial Response to Levosimendan in HELP Trial, Data Show

Preliminary data from the Phase 2 HELP study testing levosimendan as a potential treatment for pulmonary hypertension (PH) patients with heart failure and preserved ejection fraction (PH-HFpEF) showed that 86% of those analyzed responded to the therapy, with less pressure evident on heart’s left atrium. The ongoing trial’s predefined response criterion — the…

Prerequisite Response Achieved in 83% of Patients After Levosimendan Infusion in HELP Trial

Fifteen out of 18 patients (83%) enrolled in the Phase 2 HELP study testing levosimendan achieved the predefined response required in the open-label phase of the study, Tenax Therapeutics announced. The investigational therapy is a potential treatment for pulmonary hypertension (PH) and heart failure with preserved ejection fraction (PH-HFpEF). The response…